Deans' stroke musings: European Patent Office Issues Its Intention to Grant Genervon Biopharmaceuticals a European Patent on Methods of Treating Neuronal Disorders Using MNTF Peptides and Analogs Thereof

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, December 17, 2012

European Patent Office Issues Its Intention to Grant Genervon Biopharmaceuticals a European Patent on Methods of Treating Neuronal Disorders Using MNTF Peptides and Analogs Thereof

I'm not sure what research was behind this so ask your doctor. Your doctor knows everything. I'm not sure I like patenting stroke methods.
http://eon.businesswire.com/news/eon/20121217006462/en/Patent/Neuronal-Disorders/Stroke
The European Patent Office notified Genervon of its intention to grant a European patent on Methods of Treating Neuronal Disorders using MNTF peptides and analogs thereof. Genervon will proceed to have the patents for EPO application No. 07867451.2 issued, bringing the portfolio of Genervon’s issued Composition of Matters and Use patents to 46.
This patent will grant the intellectual property rights to the use of GM600 in the preparation of a medicament for the therapeutic treatment of neuronal diseases and disorders including stroke, cerebral ischemia, spinal cord injuries (SCI), Huntington’s disease (HD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease by intravenous delivery.
Genervon has discovered a novel endogenous embryonic stage family of 9 human master regulators of the nervous system. The company has developed one of the master regulators, named GM600, for disease modification in neurodegenerative diseases and for neuroprotection. A Phase 1 clinical trial in human volunteers by bolus intravenous administration was completed and GM600 is very safe and tolerable at very high multiple doses. A GM600 serial number is assigned to each indication. GM602 and GM608 are assigned to ischemic stroke and Parkinson’s disease, respectively, which are in Phase 2 clinical trials. GM604 is assigned to ALS indication, with promising and comprehensive mechanisms of action.
GM600 provided neuroprotection against soluble inflammatory factors from CNS human patients’ cerebral spinal fluid (CSF) in vitro by the following percent increase of neuronal cells: Stroke (205%), ALS (175%), MS (246%), AD (191%), HD (271%), PD (198%). GM600 has shown very efficacious effects in animal models in many neurodegenerative and acute injury models.
The discovery of endogenous embryonic stage human master regulators is changing the drug development paradigm from hitting a single gene/pathway to a comprehensive and dynamic multi-factorial approach to treat complex neurodegenerative diseases. Genervon is at the forefront of a drug development paradigm shift that is beginning to be appreciated.
Genervon Biopharmaceuticals LLC (www.genervon.com) is an innovative clinical stage biopharmaceutical company providing breakthrough biological drugs for some of the world’s critical unmet medical needs.